Patient iP's clinical trial matching solution tops 14m patient records

By Melissa Fassbender contact

- Last updated on GMT

Patient iP was launched as a clinical trial matching solution in 2015. (Image: iStock/daizuoxin)
Patient iP was launched as a clinical trial matching solution in 2015. (Image: iStock/daizuoxin)
Patient iP has been growing its Connected Site Network over the past two years – as it aims to curate one of the largest patient-centric, longitudinal clinical data sets in the world, says CEO.

Patient identification Platform (Patient iP) is a health data network supplier to the pharmaceutical and contract research organization (CRO) industries. Its Connected Site Network has more than 14m unique patient records across 4,000 practice sites.

According to the company, the solution improves the clinical trial site selection process as well as patient matching for clinical trial participation.

Michael Margiotta, Patient iP founder and CEO told us the company has focused on building the site network through direct relationships with ambulatory electronic medical record (EMR) providers, “since they have client sites that are often overlooked in clinical research activities​,” he said. “Think of all the patients that receive care at smaller single specialty practices​.”

In addition to the Network’s milestone, Patient iP has also announced a new partnership with Aprima Medical Software, an electronic health record (EHR), practice management, and revenue cycle management solutions provider.

As part of the collaboration, Aprima medical practice customers can choose to have their de-identified data processed through Patient iP’s matching engine to find possible research participants. Nearly 12m individuals have electronic records in Aprima software, according to the company.

Millions of patients

According to Margiotta, millions of patients in the US are not identified for research opportunities because the emphasis has been on large, academic research centers. However, he said many smaller physician practices would be interested in establishing a clinical research capability – if engagement from the pharma and CRO space was assured.

Margiotta explained accessing patients that have likely never participated in clinical research will enable cost savings for sponsors and CROs, “since they can access market insights about how realistic a trial is, meaning fewer downstream amendments and rescue scenarios​.”

The availability of a large volume of de-identified, patient-centric data along with our software offering is a valuable combination offering​,” he added. “We aren’t just providing data for feasibility purposes, but have the engine to overlay the data in order to process eligibility criteria and understand first of all, are there potential participants that even meet criteria and secondarily, where are they geographically speaking​.”

Margiotta told us it is this combination of data and technology that sets the company apart from other “matching” solutions.

We started out by developing a technology capable of processing complex criteria against EMR data but quickly learned that despite our solution having strong interest from research entities, many still lacked data and struggled growing site relationships​,” said Margiotta, explaining that the Site Network helps bridge that gap.

And while the data is de-identified, because it is patient-centric, the value contained within demonstrating changes in health and outcomes over time is of high value and unlike many other datasets out there that are claims or point-in-time based​,” she added.

Over the next five years, Margiotta said the company will continue expanding its solutions and value to the market and patients.

There will be many advancements over the next five years in Genomics and other more granular key indicators that will bring a new level of complexity and opportunity, and we must remain on the cutting edge to ensure we are providing the most innovative, salient solutions​,” she added.

Margiotta also said the company will continue to develop its site network “with the objective of curating one of the largest patient-centric, longitudinal clinical data sets both domestically and internationally​.”

Related news

Show more

Related products

show more


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Related suppliers